AVEO Pharmaceuticals Inc. (AVEO)

2.86
NASDAQ : Health Technology
Prev Close 2.89
Day Low/High 2.76 / 2.92
52 Wk Low/High 1.86 / 4.15
Avg Volume 2.58M
Exchange NASDAQ
Shares Outstanding 121.50M
Market Cap 351.12M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AVEO Announces Pricing Of $5.7 Million Public Offering Of Common Stock

AVEO Announces Pricing Of $5.7 Million Public Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.

AVEO Announces Proposed Offering Of Common Stock

AVEO Announces Proposed Offering Of Common Stock

AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AVEO Announces Acceptance Of CANbridge Investigational New Drug Application For CAN017 (AV-203) Trial In Esophageal Squamous Cell Cancer (ESCC) In China

AVEO Announces Acceptance Of CANbridge Investigational New Drug Application For CAN017 (AV-203) Trial In Esophageal Squamous Cell Cancer (ESCC) In China

AVEO Oncology (Nasdaq: AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences' Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO's clinical-stage...

AVEO Reports Second Quarter 2018 Financial Results And Provides Business Update

AVEO Reports Second Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2018 and provided a business update.

AVEO Oncology To Present At The Canaccord Genuity 38th Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 38th Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.

AVEO Oncology Added To The Russell 2000, Russell 3000, And Russell Microcap Indexes

AVEO Oncology Added To The Russell 2000, Russell 3000, And Russell Microcap Indexes

AVEO Oncology (NASDAQ: AVEO) today announced that it has been added to the Russell 2000 ®, Russell 3000 ®, and Russell Microcap ® Indexes, effective after the U.

AVEO Reports First Quarter 2018 Financial Results And Provides Business Update

AVEO Reports First Quarter 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2018 and provided a business update.

Interesting AVEO Put And Call Options For June 15th

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: Needham & Company's 17th Annual Healthcare...

AVEO Oncology Announces Publication Of Long-term Follow-up Results From TIVO-1 Extension Study (Study 902) In TKI Refractory RCC

AVEO Oncology Announces Publication Of Long-term Follow-up Results From TIVO-1 Extension Study (Study 902) In TKI Refractory RCC

AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA ®) as second-line treatment in advanced renal cell...

AVEO Reports Full Year 2017 Financial Results And Provides Business Update

AVEO Reports Full Year 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update.

AVEO Oncology To Present At The Cowen And Company 38th Annual Health Care Conference

AVEO Oncology To Present At The Cowen And Company 38th Annual Health Care Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38 th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at...

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA® (tivozanib) As First Line Treatment For Advanced Renal Cell Carcinoma

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation For FOTIVDA® (tivozanib) As First Line Treatment For Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA ® (tivozanib) for...

AVEO Oncology And EUSA Pharma Announce Encouraging Preliminary Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology And EUSA Pharma Announce Encouraging Preliminary Results From Phase 2 Portion Of The TiNivo Study In Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA ®) in...

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: LEERINK Partners 7th Annual Global Healthcare...

AVEO Announces Appointment Of John H. Johnson To Board Of Directors

AVEO Announces Appointment Of John H. Johnson To Board Of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H.

First Week of AVEO March 16th Options Trading

First Week of AVEO March 16th Options Trading

Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new March 16th contracts and identified the following put contract of particular interest.

AVEO Oncology Announces Presentation Of Data From Phase 1b/2 Study Of Tivozanib In Patients With Advanced Hepatocellular Carcinoma

AVEO Oncology Announces Presentation Of Data From Phase 1b/2 Study Of Tivozanib In Patients With Advanced Hepatocellular Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA ® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth...

AVEO Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 36th Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.

AVEO Oncology Announces Refinanced Debt Facility

AVEO Oncology Announces Refinanced Debt Facility

AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.

First Week of AVEO February 16th Options Trading

First Week of AVEO February 16th Options Trading

Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new February 16th contracts and identified the following call contract of particular interest.

First Week of July 2018 Options Trading For AVEO Pharmaceuticals (AVEO)

First Week of July 2018 Options Trading For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AVEO Announces Appointment Of Nikhil Mehta, Ph.D., As Senior Vice President Of Regulatory And Quality Assurance

AVEO Announces Appointment Of Nikhil Mehta, Ph.D., As Senior Vice President Of Regulatory And Quality Assurance

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.

EUSA Pharma And AVEO Oncology Announce The First Commercial Launch Of FOTIVDA® (tivozanib)

EUSA Pharma And AVEO Oncology Announce The First Commercial Launch Of FOTIVDA® (tivozanib)

EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA ® (tivozanib) with the initiation of product sales in Germany.

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology To Present At Upcoming Conferences

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference...

AVEO Reports Third Quarter 2017 Financial Results And Provides Business Update

AVEO Reports Third Quarter 2017 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update.

AVEO Oncology And EUSA Pharma Announce Promising Phase 1 Results From The Phase 1/2 TiNivo Study Of Tivozanib And Nivolumab In Renal Cell Carcinoma

AVEO Oncology And EUSA Pharma Announce Promising Phase 1 Results From The Phase 1/2 TiNivo Study Of Tivozanib And Nivolumab In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA ®) in...

TheStreet Quant Rating: D- (Sell)